Observer Variation in the Application of the Pheochromocytoma of the Adrenal Gland Scaled Score
暂无分享,去创建一个
A. Tischler | R. Lloyd | R. D. de Krijger | V. Nosé | F. V. van Nederveen | R. DeLellis | David Wu | Arthur S. Tischler | Ronald A. DeLellis
[1] Haifeng Zhao,et al. Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. , 2006, Urology.
[2] W. Dinjens,et al. New developments in the detection of the clinical behavior of pheochromocytomas and paragangliomas , 2006, Endocrine pathology.
[3] C. Larsson,et al. Pheochromocytoma and functional paraganglioma syndrome: No longer the 10% tumor , 2005, Journal of surgical oncology.
[4] N. Kimura,et al. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: A clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors , 2005, Endocrine pathology.
[5] O. Gimm. Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx , 2004, Familial Cancer.
[6] R. Hinze,et al. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas , 2004, Modern Pathology.
[7] C. Larsson,et al. KI-67 AND hTERT Expression Can Aid in the Distinction between Malignant and Benign Pheochromocytoma and Paraganglioma , 2003, Modern Pathology.
[8] S. Singh,et al. Flow Cytometric DNA Analysis for Determination of Malignant Potential in Adrenal Pheochromocytoma or Paraganglioma: An Indian Experience , 2003, Annals of Surgical Oncology.
[9] P. Gattuso,et al. Differential heparanase-1 expression in malignant and benign pheochromocytomas. , 2002, The Journal of surgical research.
[10] L. Thompson. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases , 2002, The American journal of surgical pathology.
[11] S. Asa,et al. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques , 2002, Endocrine pathology.
[12] A. Khorram-Manesh,et al. N-cadherin expression in adrenal tumors: Upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma , 2002, Endocrine pathology.
[13] P. Heikkilä,et al. Increased Expression of Tenascin in Pheochromocytomas Correlates With Malignancy , 2001, The American journal of surgical pathology.
[14] L. Layfield,et al. Prognostic Value of Immunohistochemical Expression of Topoisomerase Alpha II, MIB-1, p53, E-Cadherin, Retinoblastoma Gene Protein Product, and HER-2/neu in Adrenal and Extra-adrenal Pheochromocytomas , 2000, Applied immunohistochemistry & molecular morphology : AIMM.
[15] H. Bruining,et al. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? , 2000, The Journal of pathology.
[16] H. Bruining,et al. Prognostic value of p53, bcl‐2, and c‐erbB‐2 protein expression in phaeochromocytomas , 1999, The Journal of pathology.
[17] D. Hauri,et al. Pheochromocytomas: can malignant potential be predicted? , 1999, Urology.
[18] M. Demeure,et al. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior. , 1999, Cancer.
[19] R. Weyant,et al. Prognostic markers in pheochromocytoma. , 1998, Human pathology.
[20] L. Castilla-Guerra,et al. Expression and prognostic value of c‐erbB‐2 oncogene product in human phaeochromocytomas , 1997, Histopathology.
[21] M. Friedlander,et al. Prognostic significance of nuclear DNA content in phaeochromocytoma. , 1991, The Australian and New Zealand journal of surgery.
[22] S. Steinberg,et al. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. , 1990, Human pathology.